[Effectiveness of antiinflammatory therapy in patients with interstitial lung diseases using re-assay of biomarker mucin 3EG5].
To investigate a potential of a new marker of activity of interstitial pulmonary diseases (IPD)--mucin 3EG5--in monitoring of effectiveness of the antiinflammatory therapy. Serum mucin antigen 3EG5 (glycolyl-sialylated glycoprotein) was assessed with sandwich immunoassay constructed using a monoclonal antibody 3E1.2 (Medical Innovations, Australia) and affinity-purified polyclonal antibody G5 (Xema, Russia) against total mucin antigen family. The level of serum 3EG5 was studied in 16 IPD patients (9 had idiopathic pulmonary fibrosis and 7--chronic hypersensitivity pneumonitis) before and after 6 months of immunosuppressive therapy. By changes in pulmonary function tests during 6 months of steroid treatment all the patients were divided into two groups: responders (a 15% increase in FVC, 20% increase in DLCO and reduction in the PA-aO2 of 5 mm Hg) and nonresponders (worsening or insignificant changes in these indices). In responders (n = 7) after treatment serum levels of 3EG5 fell from 230 +/- 97 to 88 +/- 40 units/ml (p < 0.01). In nonresponders serum 3EG5 was not different before and after therapy: 249 +/- 153 and 247 +/- 170 units/m, although in this group two patients with unchanged lung function showed a significant decrease in 3EG5, so the accuracy of changes in serum 3EG5 to reflect response to therapy was 88%. There was a significant difference between the posttreatment levels of 3EG5 of the two groups of patients (p = 0.03). Successive measurements of serum mucin 3EG5 may be used for monitoring of the response to immunosuppressive therapy in IPD patients.